BusinessRhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)By Nasdaq OMXApr 9, 2018, 11:00 AM UTC
BusinessNovel treatment of hemophilia: OMRF enters license agreement with Shanghai RAAS Blood ProductsBy Nasdaq OMXFeb 13, 2018, 8:02 PM UTC
BusinessCantabio Pharmaceuticals Announces the Development of Small Molecule Chaperones of the Abeta Peptide for the Treatment of Alzheimer's Disease in Collaboration with NovAliXBy Nasdaq OMXApr 12, 2016, 4:00 PM UTC
